Resmed Cdi revenue and financials
$31.80Change from previous close: −0.62%Absolute change: −$0.20
In the fiscal year ended June 2026, Resmed Cdi reported revenue of $5.65B (+9.85% year over year). Net income was $1.52B, a net margin of 26.9%.
Fiscal year ending in June. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +9.85%
- FY to Jun 2026 vs FY to Jun 2025
- Net income growth
- +8.75%
- FY to Jun 2026 vs FY to Jun 2025
- Net margin
- 26.9%
- FY to Jun 2025: 27.2%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 1,464 | 1,431 | 1,423 | 1,336 | 1,348 | — |
| Cost of revenue | 602 | 540 | 544 | 515 | 528 | — |
| Gross profit | 861 | 891 | 879 | 821 | 820 | — |
| Selling, general and administrative | 296 | 286 | 278 | 259 | 265 | — |
| Research and development | 106 | 94.3 | 91.0 | 87.3 | 86.4 | — |
| Operating income | 449 | 500 | 498 | 462 | 457 | — |
| EBIT | 449 | 500 | 498 | 462 | 457 | — |
| EBITDA | 504 | 569 | 560 | 520 | 531 | — |
| Pre-tax income | 474 | 502 | 496 | 447 | 458 | — |
| Income tax | 90.7 | 104 | 104 | 98.3 | 78.3 | — |
| Net income | 383 | 399 | 393 | 349 | 380 | — |
| Net income to common shareholders | 383 | 399 | 393 | 349 | 380 | — |
| Basic EPS | 0.27 | 0.27 | 0.27 | — | 0.26 | 0.25 |
| Diluted EPS | 0.26 | 0.27 | 0.27 | — | 0.26 | 0.25 |
| Average shares (basic) | 1,447 | 1,453 | 1,458 | — | 1,465 | 1,467 |
| Average shares (diluted) | 1,450 | 1,457 | 1,464 | — | 1,470 | 1,472 |